Mechanisms of Active Music Engagement in Managing Acute Distress and in Improving Positive Health Outcomes in Young Children with Cancer and Their Parents
- The child is 3-8 years of age at time of enrollment
- Patients with an expected treatment course of at least 3 days to receive moderate to high intensity chemotherapy or anti-microbial therapy (children receiving chemotherapy/anti-microbial therapy are at risk for high symptom distress; 3-day treatment course is required to deliver study conditions and contributes to sample homogeneity)
- One parent/caregiver (>= 18 years of age) can be present for all sessions (study targets both child and parent/caregiver)
- The child and/or parent/caregiver do not speak English
- The child has a significant cognitive impairment that might hinder participation (determination made in consultation with attending physician, oncologist, and parents)
I. Examine the effects of proximal and distal mediators of the Active Music Engagement (AME) intervention on outcomes for young children with cancer and parents.
II. Examine moderators of the AME intervention on outcomes for young child and parent distress.
III. Explore child physical symptom distress in mediation and moderation models. (Exploratory)
OUTLINE: Participants are randomized to 1 of 2 programs.
PROGRAM A: Participants receive 3 interactive visits from a board-certified music therapist (MT-BC) for 45-60 minutes in the child's hospital room over 3 days. Participants also receive a music kit that includes hand-held rhythm instruments, puppets, and a music compact disc (CD) to use between therapist-led sessions.
PROGRAM B: Participants receive 3 visits from an MT-BC for 45-60 minutes in the child's hospital room over 3 days, and receive an illustrated storybook with audio-taped narration.
After the last visit by the music therapist, participants are followed up at 30 days.
Trial Phase Phase O
Trial Type Supportive care
Indiana University / Melvin and Bren Simon Cancer Center
- Primary ID IUSCC-0578
- Secondary IDs NCI-2018-00513
- Clinicaltrials.gov ID NCT03085927